Journal of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회지)

Korean Society of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회)
권호 표지
DOI QR코드

DOI QR Code

Synthesis and evaluation of inhibitors for Polo-box domain of Polo-like kinase 1

  • Eun Kyoung Ryu (Research Center for Bioconvergence Analysis, Korea Basic Science Institute)
  • Received : 2020.12.15
  • Accepted : 2020.12.29
  • Published : 2020.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Polo-like kinase 1 (Plk1) is a key protein in mitosis and has been validated as a target for tumor therapy. It is well known to highly overexpress in many kinds of tumor, which has been implicated as a potential biomarker for tumor treatment and diagnosis. Plk1 consists of two domains, the N-terminus kinase domain and the C-terminus polo-box domain (PBD). The inhibitors have been developed for PBD of Plk1, which were shown a high level of affinity and selectivity for Plk1 that led to mitotic arrest and apoptotic cell death. This review discusses the inhibitors for PBD of Plk1 that are suitable for in vivo tumor treatment. They can be further extended for developing in vivo imaging probes for early diagnosis of tumor.

Keywords

Acknowledgement

이 논문은 한국연구재단 중견연구자지원사업(2020R1A2C1009289)의 지원에 의하여 이루어졌으며 다른 이해관계는 없음을 밝힙니다.

References

  1. Pagliaro L, Felding J, Audouze K, Nielsen SJ, Terry RB, Krog-Jensen C, and Butcher S, Emerging classes of protein-protein interaction inhibitors and new tools for their development. Curr Opin Chem Biol 2004;8(4):442-9.
  2. Koes DR and Camacho CJ, PocketQuery: protein-protein interaction inhibitor starting points from protein-protein interaction structure. Nucleic Acids Res 2012;40(Web Server issue):W387-92.
  3. Park JE, Soung NK, Johmura Y, Kang YH, Liao C, Lee KH, Park CH, Nicklaus MC, and Lee KS, Polo-box domain: a versatile mediator of polo-like kinase function. Cell Mol Life Sci 2010;67(12):1957-70.
  4. van Vugt MA and Medema RH, Getting in and out of mitosis with Polo-like kinase-1. Oncogene 2005;24(17):2844-59.
  5. Zitouni S, Nabais C, Jana SC, Guerrero A, and Bettencourt-Dias M, Polo-like kinases: structural variations lead to multiple functions. Nat Rev Mol Cell Biol 2014;15(7):433-52.
  6. Archambault V and Glover DM, Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 2009;10(4):265-75.
  7. Petronczki M, Lenart P, and Peters JM, Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1. Dev Cell 2008;14(5):646-59.
  8. Degenhardt Y and Lampkin T, Targeting Polo-like kinase in cancer therapy. Clin Cancer Res 2010;16(2):384-9.
  9. Winkles JA and Alberts GF, Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene 2005;24(2):260-6.
  10. Spankuch-Schmitt B, Wolf G, Solbach C, Loibl S, Knecht R, Stegmuller M, von Minckwitz G, Kaufmann M, and Strebhardt K, Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 2002;21(20):3162-71.
  11. Scharow A, Raab M, Saxena K, Sreeramulu S, Kudlinzki D, Gande S, Dotsch C, Kurunci-Csacsko E, Klaeger S, Kuster B, Schwalbe H, Strebhardt K, and Berg T, Optimized Plk1 PBD Inhibitors Based on Poloxin Induce Mitotic Arrest and Apoptosis in Tumor Cells. ACS Chem Biol 2015;10(11):2570-9.
  12. Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M, Gurtler U, Garin-Chesa P, Lieb S, Quant J, Grauert M, Adolf GR, Kraut N, Peters JM, and Rettig WJ, BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007;17(4):316-22.
  13. Murugan RN, Park JE, Kim EH, Shin SY, Cheong C, Lee KS, and Bang JK, Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity. Mol Cells 2011;32(3):209-20.
  14. Strebhardt K and Ullrich A, Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006;6(4):321-30.
  15. Lee KS, Burke TR, Jr., Park JE, Bang JK, and Lee E, Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy. Trends Pharmacol Sci 2015;36(12):858-877.
  16. Normandin K, Lavallee JF, Futter M, Beautrait A, Duchaine J, Guiral S, Marinier A, and Archambault V, Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay. Sci Rep 2016;5:37581.
  17. Lee KS, Park JE, Kang YH, Kim TS, and Bang JK, Mechanisms underlying Plk1 polo-box domain-mediated biological processes and their physiological significance. Mol Cells 2014;37(4):286-94.
  18. Baby B, Antony P, Al Halabi W, Al Homedi Z, and Vijayan R, Structural insights into the polypharmacological activity of quercetin on serine/threonine kinases. Drug Des Devel Ther 2016;10:3109-3123.
  19. Lian G, Li L, Shi Y, Jing C, Liu J, Guo X, Zhang Q, Dai T, Ye F, Wang Y, and Chen M, BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells. Int J Oncol 2018;52(3):804-814.
  20. Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R, Rouyrre N, Trommeshauser D, Hoesl CE, and Munzert G, Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008;26(34):5511-7.
  21. Fode C, Motro B, Yousefi S, Heffernan M, and Dennis JW, Sak, a murine protein-serine/threonine kinase that is related to the Drosophila polo kinase and involved in cell proliferation. Proc Natl Acad Sci U S A 1994;91(14):6388-92.
  22. Fabian MA, Biggs WH, 3rd, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lelias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, and Lockhart DJ, A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23(3):329-36.
  23. Ahn M, Han YH, Park JE, Kim S, Lee WC, Lee SJ, Gunasekaran P, Cheong C, Shin SY, Sr., Kim HY, Ryu EK, Murugan RN, Kim NH, and Bang JK, A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1. J Med Chem 2015;58(1):294-304.
  24. Park JE, Hymel D, Burke TR, Jr., and Lee KS, Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents. F1000Res 2017;6:1024.
  25. Yun SM, Moulaei T, Lim D, Bang JK, Park JE, Shenoy SR, Liu F, Kang YH, Liao C, Soung NK, Lee S, Yoon DY, Lim Y, Lee DH, Otaka A, Appella E, McMahon JB, Nicklaus MC, Burke TR, Jr., Yaffe MB, Wlodawer A, and Lee KS, Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat Struct Mol Biol 2009;16(8):876-82.
  26. Kim SM, Yoon S, Choi N, Hong KS, Murugan RN, Cho G, and Ryu EK, In vivo tumor imaging using polo-box domain of polo-like kinase 1 targeted peptide. Biomaterials 2012;33(29):6915-25.
  27. Kim SM, Chae MK, Lee C, Yim MS, Bang JK, and Ryu EK, Enhanced cellular uptake of a TAT-conjugated peptide inhibitor targeting the polo-box domain of polo-like kinase 1. Amino Acids 2014;46(11):2595-603.
  28. Yim MS, Soung NK, Han EH, Min JY, Han H, Son EJ, Kim HN, Kim B, Bang JK, and Ryu EK, Vitamin E-Conjugated Phosphopeptide Inhibitor of the Polo-Box Domain of Polo-Like Kinase 1. Mol Pharm 2019;16(12):4867-4877.
  29. Gunasekaran P, Yim MS, Ahn M, Soung NK, Park JE, Kim J, Bang G, Shin SC, Choi J, Kim M, Kim HN, Lee YH, Chung YH, Lee K, EunKyeong Kim E, Jeon YH, Kim MJ, Lee KR, Kim BY, Lee KS, Ryu EK, and Bang JK, Development of a Polo-like Kinase-1 Polo-Box Domain Inhibitor as a Tumor Growth Suppressor in Mice Models. J Med Chem 2020;63(23):14905-14920.
  30. Park JE, Kim TS, Meng L, Bang JK, Kim BY, and Lee KS, Putting a bit into the polo-box domain of polo-like kinase 1. J Anal Sci Technol 2015;6(1):27.